靶向甲硫氨酸代谢在肿瘤免疫治疗中的研究进展

李琳; 郑怡兴; 黄岚

doi:10.16689/j.cnki.cn11-9349/r.2026.04.004

PDF(2788 KB)

肿瘤代谢与营养电子杂志 ›› 2026, Vol. 13 ›› Issue (4) : 478-483. DOI: 10.16689/j.cnki.cn11-9349/r.2026.04.004

专家论坛

靶向甲硫氨酸代谢在肿瘤免疫治疗中的研究进展

李琳, 郑怡兴, 黄岚

作者信息 +

Research progress in targeting methionine metabolism for cancer immunotherapy

Li Lin, Zheng Yixing, Huang Lan

Author information +

文章历史 +

摘要

肿瘤发生伴随着肿瘤细胞的代谢重编程。大量研究显示肿瘤细胞的甲硫氨酸代谢重编程促进肿瘤进展。甲硫氨酸是必需氨基酸中唯一的含硫氨基酸,是蛋白质合成、抗氧化和代谢调节的关键物质,还参与体内甲基转移过程。限制甲硫氨酸摄入的饮食作为一种代谢干预手段,已被证实可以抑制多种肿瘤生长,并改善传统肿瘤治疗的疗效。肿瘤微环境中还存在T细胞等免疫细胞,在调控肿瘤进展过程中发挥关键作用。近年来,靶向T细胞的免疫疗法已取得突破性进展,逐渐成为肿瘤治疗的基石。甲硫氨酸也是T细胞所必需的,甲硫氨酸对肿瘤细胞和免疫细胞的双重影响引起了人们对限制甲硫氨酸摄入的饮食用于肿瘤免疫治疗的担心。此外,限制甲硫氨酸摄入的饮食还可能对患者营养状态和肠道菌群带来不利影响,加重恶液质的风险等。本文概括了肿瘤细胞的甲硫氨酸代谢特征和干预策略,并总结了靶向甲硫氨酸代谢在肿瘤免疫治疗领域的研究进展。

Abstract

The metabolic remodeling represents a critical hallmark of cancer. Numerous studies have revealed that methionine metabolism reprogramming promotes tumor progression. Methionine, the only sulfur-containing amino acid among essential amino acids, is essential for protein synthesis, redox balance and metabolic regulation, also participating in the transfer of methyl groups in the body. Dietary methionine restriction has been proven to inhibit tumor growth and improve response to various anti-cancer therapies. There are other cellular components in the tumor microenvironment, including T cells as a major driver of anti-tumor immunity. T cell-targeted immunotherapy has become the cornerstone of cancer treatments in recent years. Methionine is also essential for T cells, and its dual effects on cancer cells and immune cells have raised concerns about dietary methionine restriction for cancer treatment. In addition, methionine restriction may cause side effects on nutritional status and gut microbiota, even increasing the risk of cachexia of cancer patients. Here, this review summarizes the methionine metabolism in cancer biology, and highlights the research progress on targeting methionine metabolism for cancer immunotherapy.

导出引用

李琳, 郑怡兴, 黄岚. 靶向甲硫氨酸代谢在肿瘤免疫治疗中的研究进展[J]. 肿瘤代谢与营养电子杂志. 2026, 13(4): 478-483 https://doi.org/10.16689/j.cnki.cn11-9349/r.2026.04.004

Li Lin, Zheng Yixing, Huang Lan. Research progress in targeting methionine metabolism for cancer immunotherapy[J]. Electronic Journal of Metabolism and Nutrition of Cancer. 2026, 13(4): 478-483 https://doi.org/10.16689/j.cnki.cn11-9349/r.2026.04.004

参考文献

[1] Koppenol W H, Bounds P L, Dang C V. Otto Warburg's contributions to current concepts of cancer metabolism[J]. Nat Rev Cancer, 2011, 11(5):325-337.
[2] Stine Z E, Schug Z T, Salvino J M, et al. Targeting cancer metabolism in the era of precision oncology[J]. Nat Rev Drug Discov, 2022, 21(2):141-162.
[3] Mayne S T, Playdon M C, Rock C L. Diet, nutrition, and cancer: past, present and future[J]. Nat Rev Clin Oncol, 2016, 13(8):504-515.
[4] Xiao Y, Yu T J, Xu Y, et al. Emerging therapies in cancer metabolism[J]. Cell Metab, 2023, 35(8):1283-1303.
[5] Mentch S J, Mehrmohamadi M, Huang L, et al. Histone methylation dynamics and gene regulation occur through the sensing of one-carbon metabolism[J]. Cell Metab, 2015, 22(5):861-873.
[6] Navik U, Sheth V G, Khurana A, et al. Methionine as a double-edged sword in health and disease: current perspective and future challenges[J]. Ageing Res Rev, 2021, 72:101500.
[7] Sanderson S M, Gao X, Dai Z, et al. Methionine metabolism in health and cancer: a nexus of diet and precision medicine[J]. Nat Rev Cancer, 2019, 19(11):625-637.
[8] Hoffman R M, Erbe R W. High in vivo rates of methionine biosynthesis in transformed human and malignant rat cells auxotrophic for methionine[J]. Proc Natl Acad Sci U S A, 1976, 73(5):1523-1527.
[9] Wang Z, Yip L Y, Lee J H J, et al. Methionine is a metabolic dependency of tumor-initiating cells[J]. Nat Med, 2019, 25(5):825-837.
[10] Ghergurovich J M, Xu X, Wang J Z, et al. Methionine synthase supports tumour tetrahydrofolate pools[J]. Nat Metab, 2021, 3(11):1512-1520.
[11] Yamamoto J, Inubushi S, Han Q, et al. Linkage of methionine addiction, histone lysine hypermethylation, and malignancy[J]. IScience, 2022, 25(4):104162.
[12] Kalev P, Hyer M L, Gross S, et al. MAT2A inhibition blocks the growth of MTAP-deleted cancer cells by reducing PRMT5-Dependent mRNA splicing and inducing DNA damage[J]. Cancer Cell, 2021, 39(2):209-224.
[13] Lien E C, Ghisolfi L, Geck R C, et al. Oncogenic PI3K promotes methionine dependency in breast cancer cells through the cystine-glutamate antiporter xCT[J]. Sci Signal, 2017, 10(510):eaao6604.
[14] El-Kenawi A, Berglund A, Estrella V, et al. Elevated methionine flux drives pyroptosis evasion in persister cancer cells[J]. Cancer Res, 2023, 83(5):720-734.
[15] Liao K, Cao F, Wei C, et al. The AHCY-adenosine complex rewires mRNA methylation to enhance fatty acid biosynthesis and tumorigenesis[J]. Cell Research, 2026, 36(2):152-172.
[16] Sharma P, Guo A, Poudel S, et al. Early methionine availability attenuates tcell exhaustion[J]. Nature Immunology, 2025, 26(8):1384-1396.
[17] Sinclair L V, Howden A J M, Brenes A, et al. Antigen receptor control of methionine metabolism in T cells[J]. Elife, 2019, 88:e44210.
[18] Roy D G, Chen J, Mamane V, et al. methionine metabolism shapes T helper cell responses through regulation of epigenetic reprogramming[J]. Cell Metab, 2020, 31(2):250-266.
[19] Bian Y, Li W, Kremer D M, et al. Cancer SLC43A2 alters T cell methionine metabolism and histone methylation[J]. Nature, 2020, 585(7824):277-282.
[20] Pandit M, Kil Y S, Ahn J H, et al. Methionine consumption by cancer cells drives a progressive upregulation of PD-1 expression in CD4 T cells[J]. Nature Communications, 2023, 14(1):2593.
[21] Lan T, Gao F, Cai Y, et al. The protein circPETH-147aa regulates metabolic reprogramming in hepatocellular carcinoma cells to remodel immunosuppressive microenvironment[J]. Nat Commun, 2025, 16(1):333.
[22] Hung M H, Lee J S, Ma C, et al. Tumor methionine metabolism drives T-cell exhaustion in hepatocellular carcinoma[J]. Nat Commun, 2021, 12(1):1455.
[23] Li T, Tan Y T, Chen Y X, et al. Methionine deficiency facilitates antitumour immunity by altering m(6)A methylation of immune checkpoint transcripts[J]. Gut, 2023, 72(3):501-511.
[24] Wang Q L, Chen Z, Lu X, et al. Methionine metabolism dictates PCSK9 expression and antitumor potency of PD-1 blockade in mss colorectal cancer[J]. Adv Sci (Weinh), 2025, 12(19):e2501623.
[25] Hoffman R M, Hoshiya Y, Guo W. Efficacy of methionine-restricted diets on cancers in vivo[J]. Methods Mol Biol, 2019, 1866:75-81.
[26] Hoffman R M. Clinical studies of methionine-restricted diets for cancer patients[J]. Methods Mol Biol, 2019, 1866:95-105.
[27] Xu Q, Li Y, Gao X, et al. HNF4alpha regulates sulfur amino acid metabolism and confers sensitivity to methionine restriction in liver cancer[J]. Nat Commun, 2020, 11(1):3978.
[28] Lu W C, Saha A, Yan W, et al. Enzyme-mediated depletion of serum l-Met abrogates prostate cancer growth via multiple mechanisms without evidence of systemic toxicity[J]. Proc Natl Acad Sci U S A, 2020, 117(23):13000-13011.
[29] Klionsky D J, Petroni G, Amaravadi R K, et al. Autophagy in major human diseases[J]. EMBO J, 2021, 40(19):e108863.
[30] 周子逸,刘德梅, 许萍. 一碳代谢相关营养素与肿瘤关系[J/CD]. 肿瘤代谢与营养电子杂志,2023,10(1):22-28.
[31] Gao X, Sanderson S M, Dai Z, et al. Dietary methionine influences therapy in mouse cancer models and alters human metabolism[J]. Nature, 2019, 572(7769):397-401.
[32] Fang L, Hao Y, Yu H, et al. Methionine restriction promotes cGAS activation and chromatin untethering through demethylation to enhance antitumor immunity[J]. Cancer Cell, 2023, 41(6):1118-1133.
[33] Strekalova E, Malin D, Good D M, et al. Methionine deprivation induces a targetable vulnerability in triple-negative breast cancer cells by enhancing TRAIL receptor-2 expression[J]. Clin Cancer Res, 2015, 21(12):2780-2791.
[34] Li F, Liu P, Mi W, et al. Blocking methionine catabolism induces senescence and confers vulnerability to GSK3 inhibition in liver cancer[J]. Nat Cancer, 2024, 5(1):131-146.
[35] Topalian S L, Taube J M, Pardoll D M. Neoadjuvant checkpoint blockade for cancer immunotherapy[J]. Science, 2020, 367(6477):eaax0182.
[36] Hegde P S, Chen D S. Top 10 challenges in cancer immunotherapy[J]. Immunity, 2020, 52(1):17-35.
[37] Mu H, Zhang Q, Zuo D, et al. Methionine intervention induces PD-L1 expression to enhance the immune checkpoint therapy response in MTAP-deleted osteosarcoma[J]. Cell Rep Med, 2025, 6(3):101977.
[38] Xue Y, Lu F, Chang Z, et al. Intermittent dietary methionine deprivation facilitates tumoral ferroptosis and synergizes with checkpoint blockade[J]. Nat Commun, 2023, 14(1):4758.
[39] Huang Y, Qin G, Cui T, et al. A bimetallic nanoplatform for STING activation and CRISPR/Cas mediated depletion of the methionine transporter in cancer cells restores anti-tumor immune responses[J]. Nat Commun, 2023, 14(1):4647.
[40] Zhou S, Zhang S, Zheng K, et al. Salmonella-mediated methionine deprivation drives immune activation and enhances immune checkpoint blockade therapy in melanoma[J]. J Immunother Cancer, 2024, 12(2):e008238
[41] Sun T Z Q, Dai Y, Liu Y, et al. Methionine-depleting engineered probiotics promote PD-L1 antibody immunotherapy by activating the STING pathway[J]. Biomaterials, 2026, 330:124015.
[42] Yang H, Zingaro V A, Lincoff J, et al. Remodelling of the translatome controls diet and its impact on tumorigenesis[J]. Nature, 2024, 633(8028):189-197
[43] Ji M, Xu X, Xu Q, et al. Methionine restriction-induced sulfur deficiency impairs antitumour immunity partially through gut microbiota[J]. Nature Metabolism, 2023, 5(9):1526-1543.
[44] Lin K, Wei L, Wang R, et al. Disrupted methionine cycle triggers muscle atrophy in cancer cachexia through epigenetic regulation of REDD1[J]. Cell metabolism, 2025, 37(2):460-476.e468.
[45] Ma S, Zhu W, Ji X, et al. Multiplex methionine modulating hydrogel for cancer metabolic therapy[J]. Adv Mater, 2025, 37(30):e2420445.
[46] Gu Y, Nguyen B L, Mishra S, et al. Nanoparticle-based methionine and AICAR delivery elicits a robust antitumor immune response[J]. J Control Release, 2025, 385:113981.